PCSK9 and familial hyperaldosteronism: PCSK9 inhibitors, namely evolocumab and alirocumab, can reduce LDL-C levels by approximately 20–25% and 55–60% in homozygous FH patients and people with severe heterozygous FH, respectively [110].